BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.4% – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price dropped 4.4% during trading on Wednesday . The company traded as low as $7.91 and last traded at $7.95. Approximately 3,370,497 shares changed hands during mid-day trading, an increase of 22% from the average daily volume of 2,757,389 shares. The stock had previously closed at $8.31.

Analyst Upgrades and Downgrades

Several analysts recently commented on BCRX shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Evercore ISI raised their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Down 3.1 %

The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -13.20 and a beta of 1.75. The firm has a fifty day moving average price of $8.14 and a 200-day moving average price of $7.87.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same period last year, the business earned $0.28 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% compared to the same quarter last year. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $33,000. Venturi Wealth Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $46,000. R Squared Ltd acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $48,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 4,537 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.